Wimalawansa S J
Department of Medicine (Endocrinology), Royal Postgraduate Medical School, London, UK.
Calcif Tissue Int. 1993 Feb;52(2):90-3. doi: 10.1007/BF00308314.
Forty-three patients were treated for a total duration of 301 patient-years with calcitonin (CT) (range 3-16 years, median duration 6 years 6 months). Eighty-four percent of patients were suffering from complications associated with Paget's disease and the remainder from osteoporosis. In the majority of patients, CT was administered by the subcutaneous route and one patient was psychologically dependent on calcitonin injections. There were no long-term side effects associated with CT therapy. In a separate group of 105 patients consisting of 83 patients on human CT and 22 patients on salmon CT, injections showed short-term side effects in 77% and 64% of these patients, respectively (NS). Side effects associated with nasally administered salmon CT in 25 patients were mild and of low incidence (32%). Long-term administration of calcitonin in humans is safe and devoid of any serious or long-term side effects.
43例患者接受降钙素（CT）治疗，总疗程为301患者年（范围3 - 16年，中位疗程6年6个月）。84%的患者患有与佩吉特病相关的并发症，其余患者患有骨质疏松症。大多数患者通过皮下途径给药CT，有1例患者对降钙素注射存在心理依赖。CT治疗未出现长期副作用。在另一组105例患者中，83例使用人CT，22例使用鲑鱼CT，这些患者中分别有77%和64%出现注射相关的短期副作用（无显著性差异）。25例经鼻给予鲑鱼CT的患者出现的副作用较轻，发生率较低（32%）。降钙素在人体的长期给药是安全的，且无任何严重或长期副作用。
